# Obsessive-Compulsive Disorder

Manage OCD by measuring impairment and symptom severity, delivering exposure and response prevention or an SSRI, and reserving augmentation for persistent symptoms after verified adequate first-line treatment.

**Clinical question:** How should physicians assess, treat, and escalate care for adults and adolescents with obsessive-compulsive disorder?

Updated: 2026-08-24T18:50:26.891511+00:00

## What matters in practice
- Use the clinician-rated Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to establish baseline severity and track treatment response; a 35% reduction is a conventional response threshold, and approximately 5 points is a minimal clinically important difference. [10]
- Cognitive behavioral therapy incorporating exposure and response prevention (ERP) and serotonin reuptake inhibition are first-line treatments; combining psychotherapy with an antidepressant can outperform either modality alone. [2][22][23][24]
- Before labeling OCD treatment resistant, verify adherence, adverse effects, adequacy of prior medication and ERP exposure, comorbid depression and suicide risk, and psychosocial barriers. [21]
- For persistent symptoms after an adequate SRI trial, consider another SSRI or clomipramine; antipsychotic augmentation is off-label and is most appropriate after a partial rather than absent antidepressant response. [22][24]
- Children, adolescents, adults younger than 30 years, patients with comorbid depression, and those at elevated suicide risk require close early monitoring when an SSRI is started. [21]

## Establish severity, functional risk, and treatment targets

Measure symptoms before selecting monotherapy, combined treatment, or specialty escalation.

At the first evaluation, document the dominant obsessional themes, compulsions, avoidance, time consumed, degree of insight, functional impairment, and family accommodation. Use the Y-BOCS symptom checklist in a semistructured interview to identify specific current and past symptoms; the checklist includes more than 60 symptoms organized by theme. [12] In children, symptoms occurring more than 1 hour daily, causing substantial distress, or interfering with activities support clinically significant illness requiring formal evaluation. [17]

Obtain a baseline clinician-rated Y-BOCS and repeat it during treatment to distinguish subjective improvement from clinically meaningful change. Traditional Y-BOCS benchmarks are 0-7 subclinical, 8-15 mild, 16-23 moderate, 24-31 severe, and 32-40 extreme. A Y-BOCS reduction of at least 35% is a conventional response criterion; the estimated minimal clinically important difference is 4.9 points. [10] For the self-report Y-BOCS-SR, scores average 2.23 points lower than clinician-rated scores; use adjusted severity benchmarks of 0-11 subclinical, 12-19 mild, 20-27 moderate, and 28-40 severe, with a clinical cutoff of 12 or higher. [10]

At each intake and medication change, assess suicidal ideation, self-harm risk, depressive symptoms, psychosocial stressors, and treatment-interfering factors. For patients referred for specialist multidisciplinary care, the assessment should explicitly review prior psychological and pharmacologic treatment, adherence, adverse effects, comorbidities, family or caregiver relationships, and personality factors. [21] Escalate urgently according to the level of suicide or self-harm risk rather than waiting for OCD-specific treatment response.
- Record a Y-BOCS total score and the individual symptom targets that will anchor ERP and medication follow-up. [10][12]
- Identify tic disorders, particularly in children, because OCD can co-occur with Tourette syndrome or other tic disorders. [17]
- Do not equate OCD with cleanliness or orderliness; a theme-based symptom inventory prevents missed harm, checking, taboo-thought, symmetry, and mental-ritual presentations. [12][17]

*Y-BOCS severity interpretation and response targets. [10]*

| Measure | Interpretation | Use in management |
| --- | --- | --- |
| Clinician-rated Y-BOCS 0-7 | Subclinical symptoms. [10] | Use as a reference range when judging residual symptoms and remission. [10] |
| Clinician-rated Y-BOCS 8-15 | Mild symptoms. [10] | Assess functional impairment and patient preference when deciding between ERP, medication, or both. [10][22] |
| Clinician-rated Y-BOCS 16-23 | Moderate symptoms. [10] | Initiate evidence-based ERP and/or serotonin reuptake inhibition; quantify change at follow-up. [2][22][23] |
| Clinician-rated Y-BOCS 24-31 or 32-40 | Severe or extreme symptoms, respectively. [10] | Favor a structured treatment plan with objective monitoring and assess need for combined treatment or specialist review. [10][21][24] |
| Change from baseline | At least 35% Y-BOCS reduction is a conventional response; approximately 4.9 points is a minimal clinically important difference. [10] | Continue, optimize, or escalate treatment using measured rather than impressionistic response. [10] |

## Choose ERP, serotonin reuptake inhibition, or both

First-line treatment should deliver OCD-specific behavioral therapy or a serotonin reuptake inhibitor rather than nonspecific supportive psychotherapy alone.

Offer cognitive behavioral therapy that includes exposure and response prevention as a first-line intervention. CBT and serotonin reuptake inhibiting medications are recommended treatments in children and adolescents, and ERP-based CBT is a first-line strategy across OCD treatment reviews and guidelines. [2][22][23][24] ERP requires planned exposure to feared cues while preventing rituals or reassurance-seeking responses; use the Y-BOCS symptom profile to select targets and monitor change. [10][12]

Use an SSRI when medication is preferred, ERP is inaccessible or not feasible, symptoms remain impairing, or combined treatment is indicated. Fluoxetine, fluvoxamine, paroxetine, sertraline, and clomipramine are identified as FDA-approved medication options for OCD in the cited review, while prolonged SSRI administration is emphasized as most effective. [9][22] Because clomipramine is a serotonin reuptake inhibitor with a different adverse-effect and interaction burden than SSRIs, use it as a deliberate alternative rather than casually combining serotonergic agents. A reported clomipramine augmentation trial included a discontinuation for serotonin syndrome, underscoring the need to assess interaction risk when combining serotonergic medications. [23]

When both modalities are available, discuss combined ERP-based CBT plus antidepressant treatment, particularly when baseline impairment is substantial or either modality alone has produced incomplete benefit. Combined CBT and antidepressant therapy has been reported as more effective than either alone. [22][24] If ERP is declined or treatment engagement is limited, identify the barrier and offer an SSRI rather than leaving clinically impairing OCD untreated; exposure-based treatment is demanding, and approximately 40% of people offered CBT with ERP may refuse or discontinue it. [8]
- Specify ERP in the referral order; generic counseling or nonspecific CBT does not establish that exposure and response prevention is being delivered. [22][23][24]
- For children and adolescents, involve family or caregivers in CBT with ERP when treating moderate to severe functional impairment. [21]
- Use routine symptom monitoring at treatment sessions and ensure therapy is delivered by a competent, supervised clinician using an evidence-based manual when possible. [4]

### SSRI monitoring in younger and higher-risk patients

If an SSRI is started in a child or adolescent because psychological treatment is declined or cannot be engaged, arrange careful monitoring for adverse events. [21] Monitor carefully and frequently during early SSRI treatment in adults younger than 30 years, patients with comorbid depression, and patients considered at increased suicide risk because of the potential for suicidal thoughts and self-harm early in treatment. [21]
- At follow-up, document adverse effects, suicidal thoughts or self-harm, adherence, Y-BOCS change, and whether ERP participation is occurring. [10][21]
- If early adverse effects or activation compromise adherence, reassess the medication plan promptly rather than interpreting discontinuation as pharmacologic nonresponse. [21]

*First-line OCD treatment selection. [2][21][22][23][24]*

| Clinical situation | Preferred next action | Key implementation point |
| --- | --- | --- |
| Patient can engage in behavioral treatment | Offer CBT with ERP. [2][22][23][24] | Use the symptom checklist and baseline Y-BOCS to build exposure targets and measure response. [10][12] |
| Medication is preferred, ERP is unavailable, or engagement is not possible | Use an SSRI; clomipramine is another approved serotonin reuptake inhibitor option. [9][21][22] | Monitor adverse effects, adherence, and suicide-related risk closely in younger or higher-risk patients. [21] |
| Moderate-to-severe impairment with incomplete response to one modality | Use combined ERP-based CBT and antidepressant treatment. [21][22][24] | Measure improvement with serial Y-BOCS scores rather than relying on global impression alone. [10] |
| Child age 8-11 or adolescent age 12-18 with moderate-to-severe impairment after inadequate family-involved CBT with ERP | After multidisciplinary review, consider adding an SSRI while continuing psychological treatment. [21] | Continue careful adverse-event monitoring. [21] |

## Confirm an adequate first-line trial before escalating

Apparent refractoriness often reflects incomplete delivery, intolerance, nonadherence, or unaddressed comorbidity.

Before changing therapy, determine whether the patient received an adequate dose and duration of the prescribed serotonin reuptake inhibitor, whether adherence was consistent, and whether ERP actually included exposure with ritual prevention. One commonly cited operational definition of refractory OCD requires failure of adequate SSRI and psychotherapy trials, with approximately 12 weeks of continuous maximum-tolerated SSRI or clomipramine treatment and at least 30 hours of psychotherapy; this is a proposed threshold rather than a universal standard. [7] Use serial Y-BOCS scores to determine whether there is partial response, no response, or worsening. [10]

Reassess diagnostic and clinical modifiers before pharmacologic escalation: symptom profile, comorbid depression, suicide risk, tic disorder, psychosocial stressors, family accommodation, medication adverse effects, and treatment acceptability. [17][21] In particular, distinguish a partial medication response from an absent response: augmentation may preserve a beneficial antidepressant effect in partial responders, whereas another SSRI or clomipramine is a reasonable alternative after inadequate benefit from the prior agent. [22][24]

Persistent impairment after adequate first-line treatment warrants review by clinicians with OCD-specific expertise, especially for children and adolescents and for patients considering multi-drug regimens. NICE recommends multidisciplinary review before adding an SSRI to ongoing family-involved CBT with ERP in young people with moderate-to-severe functional impairment who have not responded adequately to CBT. [21]
- Do not call OCD treatment resistant solely because symptoms persist after a brief or poorly adherent medication exposure. [7][21]
- Document whether the prior intervention was ERP-based and whether treatment dropout reflected the intensity of exposure work, adverse effects, access barriers, or patient preference. [8][21]
- Use partial response to an SRI as the principal pharmacologic branch point: preserve and augment a helpful agent versus switch after inadequate benefit. [24]

*Escalation framework for persistent OCD symptoms. [7][10][21][22][24]*

| Finding at reassessment | Interpretation | Next step |
| --- | --- | --- |
| No documented adequate medication exposure, adherence, or ERP delivery | Insufficient basis to classify treatment resistance. [7][21] | Correct adherence, tolerability, access, and ERP implementation; then reassess with Y-BOCS. [10][21] |
| Partial response to an SSRI but residual impairing symptoms | Maintaining the SRI while adding a treatment may preserve existing benefit. [24] | Add or intensify ERP; consider off-label antipsychotic augmentation after an adequate SRI trial. [22][24] |
| Inadequate response to one adequate SRI trial | Another SSRI or clomipramine is a recognized next pharmacologic strategy. [22] | Select the next agent with attention to prior adverse effects and interaction risk. [21][23] |
| Child or adolescent with persistent moderate-to-severe impairment after family-involved CBT with ERP | Requires specialist-level treatment review before medication addition. [21] | After multidisciplinary review, consider SSRI addition while continuing psychological treatment. [21] |

## Use antipsychotic augmentation selectively and monitor its tradeoffs

Antipsychotic augmentation is an off-label option for carefully selected patients with persistent symptoms after adequate serotonin reuptake inhibition.

For treatment-resistant OCD with a partial response to an SSRI or clomipramine, consider low-dose antipsychotic augmentation only after confirming adequate first-line treatment and discussing off-label status. Meta-analytic and review evidence supports benefit for some patients from antipsychotic augmentation, and cited guidelines identify risperidone, haloperidol, olanzapine, and quetiapine as more effective with an SSRI than SSRI monotherapy; aripiprazole may also help. [9][20][22][23][24] Antipsychotic augmentation should not replace ERP, which remains a first-line intervention. [22][23][24]

Use the agent-specific adverse-effect profile to guide selection and follow-up. In a single-blind trial of patients with established SSRI resistance, risperidone 1-3 mg/day and olanzapine 2.5-10 mg/day produced no significant difference in OCD outcome; amenorrhea occurred more commonly with risperidone, whereas weight gain was associated with olanzapine. [23] A separate treatment discussion notes that a patient receiving risperidone 2 mg required continued observation because maximal benefit from a recent dose increase may not yet have occurred. [24] Track Y-BOCS change and adverse effects rather than continuing an ineffective augmentation indefinitely. [10][24]

Avoid indiscriminate multi-drug escalation. Evidence for glutamatergic and other adjunctive approaches is less established than for antipsychotic augmentation, and antipsychotic use for OCD remains off-label. [9][24] Refer complex cases for OCD-focused psychiatric review when considering clomipramine combinations, antipsychotic augmentation, or repeated pharmacologic failures, particularly if depression, suicidality, poor adherence, or family conflict complicates treatment. [21][23][24]
- Risperidone: trial evidence cited at 1-3 mg/day; monitor for amenorrhea and other clinically relevant adverse effects. [23]
- Olanzapine: trial evidence cited at 2.5-10 mg/day; weigh potential benefit against weight gain. [23]
- Aripiprazole: evidence supports possible benefit as an augmenting option, but use is off-label for OCD. [9][24]
- Continue objective Y-BOCS monitoring; a 35% reduction from baseline is a conventional response threshold. [10]

*Medication escalation options after adequate first-line treatment. [9][22][23][24]*

| Strategy | When to consider | Important tradeoff |
| --- | --- | --- |
| Switch to another SSRI | Persistent symptoms after an adequate initial SSRI trial. [22] | Reassess adherence and adverse effects before defining failure. [21] |
| Switch to or optimize clomipramine | Persistent symptoms after first-line treatment when a different serotonin reuptake inhibitor strategy is appropriate. [9][22][24] | Assess serotonergic interaction risk; serotonin syndrome caused discontinuation in a reported combination trial. [23] |
| Risperidone augmentation | Partial SRI response with persistent impairment after adequate treatment; off-label. [20][24] | Trial range cited at 1-3 mg/day; amenorrhea was more common than with olanzapine in one trial. [23] |
| Olanzapine augmentation | Alternative off-label augmentation approach after adequate SRI treatment. [9][23] | Trial range cited at 2.5-10 mg/day; weight gain was associated with olanzapine. [23] |
| Aripiprazole augmentation | Potential off-label alternative when augmentation is indicated. [9][24] | Monitor efficacy and adverse effects objectively; do not substitute it for ERP. [10][24] |

## Monitor measurable response and sustain treatment engagement

Longitudinal care should track symptoms, functioning, treatment exposure, and safety at every decision point.

At each follow-up, compare the current Y-BOCS with baseline, document change in target rituals and avoidance, ask about functional recovery, and verify medication adherence and ERP participation. A Y-BOCS reduction of at least 35% indicates conventional response, while a reduction near 5 points may still represent a patient-important change. [10] Use these measurements to decide whether to continue, optimize, switch, or augment treatment.

Address treatment dropout directly. ERP can be declined or discontinued because of its demands, so patients who disengage should be offered a revised hierarchy, structured support for treatment participation, or medication treatment rather than being categorized as unwilling to improve. [8][21] For young patients, incorporate family or caregiver involvement in psychological treatment and monitor for adverse events if an SSRI is added. [21]

OCD often follows a chronic course and may worsen without treatment; therefore, maintain active follow-up after initial improvement rather than stopping assessment once acute distress decreases. [23] Continue to screen for depression, suicidal thinking, adverse effects, and psychosocial stressors that alter the safety or feasibility of the treatment plan. [21]
- Repeat the same severity instrument whenever feasible; clinician-rated and self-report Y-BOCS scores should not be interpreted interchangeably without accounting for their score difference. [10]
- Record the reason for any treatment change: inadequate response, partial response, adverse effect, nonadherence, ERP nonengagement, or change in suicide risk. [21][24]
- Reconsider specialty care when sequential SRI strategies, ERP, and an indicated augmentation approach fail to reduce meaningful impairment. [21][22][24]

*Follow-up data that change OCD management. [10][21][24]*

| Follow-up datum | Decision implication |
| --- | --- |
| Y-BOCS decline of at least 35% | Supports conventional treatment response; continue the effective strategy while monitoring residual impairment. [10] |
| Y-BOCS decline of approximately 5 points without 35% reduction | May still be a minimal clinically important improvement; assess functional benefit before declaring failure. [10] |
| Persistent symptoms with missed doses, adverse effects, or no ERP participation | Address delivery and tolerability before medication escalation. [21] |
| Partial SRI response with continued impairment | Consider intensified ERP or carefully monitored off-label augmentation rather than automatically switching. [24] |
| New suicidality, self-harm, or worsening depression | Increase clinical monitoring and alter level of care according to risk. [21] |

## References
1. Management of obsessive-compulsive disorder in adults — www.bmj.com — https://www.bmj.com/content/392/bmj-2024-083443/rapid-responses
2. Obsessive-compulsive disorder in children and adolescents — adc.bmj.com — http://adc.bmj.com/content/archdischild/100/5/495.full.pdf
3. Long-term effects of psychotherapy in children and ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/15/11/e103872
4. OCD? Not Me! Protocol for the development and ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/5/4/e007486
5. Assessment and management of anxiety disorders ... — adc.bmj.com — https://adc.bmj.com/content/99/7/674
6. Innovation in treating obsessive-compulsive disorder will ... — www.bmj.com — https://www.bmj.com/content/392/bmj.s472.full.pdf
7. Treatment refractory OCD | The BMJ — www.bmj.com — https://www.bmj.com/rapid-response/2011/10/31/treatment-refractory-ocd
8. Rapid responses - Obsessive-compulsive disorder — www.bmj.com — https://www.bmj.com/content/333/7565/424/rapid-responses
9. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-47931-x
10. Benchmarking empirical severity for the Yale-Brown Obsessive Compulsive Scale-Second Edition — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0165032725011619
11. Inhibitory control in obsessive compulsive disorder — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2213158222003333
12. Integrating behavioral theory with OCD assessment using the Y-BOCS/CY-BOCS symptom checklist — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2211364912000267
13. Defining clinical severity in adults with obsessive–compulsive disorder — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0010440X15001388
14. Measurement Issues: The measurement of obsessive ... — acamh.onlinelibrary.wiley.com — https://acamh.onlinelibrary.wiley.com/doi/10.1111/camh.12218
15. Supplemental Information — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/85858/cdc_85858_DS5.pdf
16. Descriptive phenotype of obsessive compulsive symptoms ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/56744/cdc_56744_DS1.pdf
17. Obsessive-Compulsive Disorder in Children | Children’s Mental Health | CDC — www.cdc.gov — https://www.cdc.gov/children-mental-health/about/obsessive-compulsive-disorder-in-children.html
18. Mental Health Surveillance Among Children — www.cdc.gov — https://www.cdc.gov/mmwr/volumes/71/su/su7102a1.htm
19. Diffusion-Tensor MR Imaging Study at 3.0 T | Radiology — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.11101971
20. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576518
21. Recommendations | Obsessive-compulsive disorder and body dysmorphic disorder: treatment  | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/cg31/chapter/Recommendations#steps-3-to-5-treatment-options-for-people-with-ocd-or-bdd
22. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD) - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30101713
23. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343405?term=
24. Moving beyond first-line treatment options for OCD — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645290

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.